Beyond the good 1B results there is also a clear indication that BTX1503 reduces the excessive sebum that causes acne:
.....there were no severe adverse events recorded and the incidence of other adverse events was very low. The most common adverse event was mild dryness, which is consistent with the mechanism of action of BTX 1503....
And getting underway this quarter is an actual acne patient study utilising a number of dermatology clinics in Australia, this is one of the best small cap stock one can possibly hold, I.M.O.
BOT Announce Successful Phase 1 Study for BTX1503, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
-0.005(3.23%) |
Mkt cap ! $303.9M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 14.8¢ | $1.203M | 7.997M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 1389952 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 3238260 | 66 |
View Market Depth
| Last trade - 12.59pm 21/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |